VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PGENPrecigen, Inc.
$5.86$1.8B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksPGENCash Flow

Precigen, Inc. (PGEN) Cash Flow Statement

15Y historyFree accessUpdated daily

The company's liquidity position is deteriorating, highlighted by a negative 189.6% free cash flow margin in 2026Q1 and a $40.5M working capital outflow that underscores persistent cash consumption.

PGEN Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Cash from Operations-115.33M-87.83M-68.17M-66.93M-65.05M-55.77M-77.02M-77.02M-124.24M-104.14M-55.98M35.67M-19.86M-53.68M-61.53M-81.76M
Operating CF Margin %--906.97%-1736.89%-1075.18%-241.72%-390.91%-240.75%-240.75%-77.37%-45.09%-29.32%20.55%-27.61%-225.94%-441.86%-1020.32%
Operating CF Growth %-363.07%-28.84%-1.86%-2.9%-16.63%27.59%0%38.01%-19.3%-86.05%-256.93%279.62%63.01%12.75%24.74%-
Net Income-204.42M-250.64M-126.23M-95.9M28.32M-92.17M-170.52M-170.52M-514.71M-126.82M-190.27M-87.99M-85.62M-40.91M-81.87M-85.28M
Depreciation & Amortization3.67M3.2M4.53M6.67M10.77M13.76M17.52M17.52M33.11M31.14M24.57M17.74M10.41M7.21M7.98M4.34M
Stock-Based Compensation11.2M10.87M9.47M9.89M10.21M13.9M18.37M18.37M46.99M52.69M52.98M100.42M22.34M3.04M1.55M992K
Deferred Taxes00-1.79M-479K-150K-167K-156K-156K-21.28M-2.53M-3.47M1.12M17.86M-16.19M6.67M2.68M
Other Non-Cash Items110.32M142.12M41.34M-4.17M-78.48M9.7M78.42M78.42M351.63M15.95M77.95M-54.44M2.71M1.48M-2.04M210K
Working Capital Changes-36.1M6.62M4.52M17.07M-35.7M-804K-20.65M-20.65M-19.98M-74.58M-17.74M58.83M12.44M-8.31M6.19M-4.69M
Change in Receivables-25.64M-3.2M414K12.23M-13.51M-6.56M4.33M4.33M-2.7M740K2.59M-12.14M4.33M-644K-121K33K
Change in Inventory-11.14M-9.21M002.34M-1.9M2.51M2.51M-478K663K3.81M-774K-7.31M-4.56M98K155K
Change in Payables-628K8.77M1.55M-2.42M379K420K-1.1M-1.1M4.68M-3.4M3.62M-3.26M1.27M-43K-1.23M-388K
Cash from Investing25.89M-1.53M-20.71M-3.09M226.42M-74.54M27.78M27.78M-151.21M104.33M-28.39M-260.81M-26.03M-223.66M-23.64M-64.1M
Capital Expenditures-2.23M-2M-8.58M-1.54M-4.92M-7.25M-7.53M-7.53M-41.59M-46.67M-31.63M-12.75M-6.37M-1.53M-7.49M-13M
CapEx % of Revenue7.07%20.6%218.7%24.67%18.3%50.8%23.53%23.53%25.9%20.2%16.57%7.34%8.86%6.43%53.8%162.27%
Acquisitions0000000-10.83M-14.9M-23.35M-18.79M-137.37M-70.45M-4.48M-6M-28.66M
Investments----------------
Other Investing46.32M060K98K162.9M6.76M73.67M84.5M17.77M736K-2.69M-40K-1.32M-20K-166K300K
Cash from Financing90.84M90.05M110.58M29.59M-155.29M121.19M32.7M32.7M309.8M4.28M12.06M333.25M24M316.45M75.94M148.11M
Debt Issued (Net)92.82M92.82M0-43.22M-155.29M-466K-2.41M-2.41M219.47M-781K-395K-3.19M-2.23M389K-77K14.88M
Equity Issued (Net)770K310K110.24M72.81M0121.05M35M35M87.99M13.69M0342.7M25M318.8M75.56M135.72M
Dividends Paid0000000000000000
Share Repurchases0000000000-518K00-5K00
Other Financing-2.75M-3.08M346K01K608K117K117K2.34M-8.62M12.46M-6.25M1.23M-2.73M457K-2.49M
Net Change in Cash1.42M717K21.67M-40.75M5.25M-8.91M-16.18M-16.18M34.64M5.5M-73.17M108.32M-22.04M39.11M-9.22M2.26M
Free Cash Flow-117.57M-89.83M-76.76M-68.47M-69.97M-63.02M-84.55M-84.55M-165.83M-150.81M-87.6M22.92M-26.23M-55.21M-69.02M-94.76M
FCF Margin %-372.11%-927.57%-1955.59%-1099.86%-260.02%-441.7%-264.28%-264.28%-103.27%-65.29%-45.88%13.2%-36.46%-232.37%-495.66%-1182.59%
FCF Growth %-56.21%-17.03%-12.11%2.15%-11.03%25.46%0%49.01%-9.96%-72.14%-482.22%187.38%52.49%20.01%27.16%-
FCF per Share-0.38-0.29-0.29-0.28-0.35-0.32-0.51-0.55-1.28-1.26-0.740.21-0.26-1.35-12.47-16.73
FCF Conversion (FCF/Net Income)0.58x0.35x0.54x0.70x-2.30x0.61x0.45x0.45x0.24x0.89x0.30x-0.42x0.24x1.38x0.75x0.96x
Interest Paid007K1.17M8.54M7.16M7.2M7.2M3.87M617K964K1.2M158K51K12K18K
Taxes Paid004K21K036K48K48K216K566K10K1.17M0000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

High cash burn dependency

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Disconnect Masks Cash Drain

As reported in recent financial statements, Precigen's OCF/NI ratio reached 5.53 in 2026Q1, highlighting a significant divergence where operating cash outflows substantially exceed accounting losses, suggesting that the company's net income figures fail to capture the full extent of its ongoing cash-based operational requirements.

The persistent gap between net income and operating cash flow indicates that the company's accrual-based accounting does not reflect the immediate liquidity pressure of its R&D-heavy business model. Investors should monitor this ratio as it suggests that the company's cash burn is accelerating faster than its reported bottom-line losses might imply.

Persistent FCF Deficits Impede Sustainability

Based on the provided cash flow data, Precigen's free cash flow margin reached a negative 189.6% in 2026Q1, illustrating a deepening trend of cash consumption that consistently outpaces the company's ability to generate internal funding from its clinical-stage operations.

The trajectory of FCF remains deeply negative, with no evidence of a narrowing gap between cash inflows and outflows. This trend suggests that the company remains entirely dependent on external financing to maintain its current clinical pipeline, leaving little room for operational error.

Working Capital Volatility Signals Instability

According to quarterly cash flow filings, Precigen experienced a significant working capital outflow of $40.5M in 2026Q1, a sharp reversal from previous periods that indicates unpredictable timing in milestone-related collections and potential inefficiencies in managing its current asset and liability cycles.

The extreme swings in working capital changes suggest that the company's cash position is highly sensitive to the timing of partner payments and internal project expenditures. Such volatility warrants further investigation into whether these fluctuations are structural or merely reflective of the lumpy nature of milestone-based revenue recognition.

SBC Masks True Operational Costs

As indicated by the company's cash flow statements, stock-based compensation consistently adds back millions to operating cash flow, with $3.0M recorded in 2026Q1, which effectively obscures the true economic cost of talent retention in a highly competitive biotechnology labor market.

While SBC is a non-cash expense, its consistent presence suggests that the company relies heavily on equity-based incentives to preserve cash. This practice may be necessary for survival, but it dilutes existing shareholders and masks the true cash-based cost of operating the business.

PGEN — Frequently Asked Questions

Quick answers to the most common questions about buying PGEN stock.

How much cash does Precigen, Inc. (PGEN) generate from operations?

Precigen, Inc. (PGEN) generated $-87.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Precigen, Inc.'s free cash flow?

Precigen, Inc. (PGEN) reported negative free cash flow of $89.8M in 2025, indicating capital requirements exceeded cash from operations.

What is Precigen, Inc.'s capital expenditure (CapEx)?

Precigen, Inc. (PGEN) spent $2.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.